

July, 2011

**WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE**

NAME: Curt Daniel Furberg, M.D., Ph.D.

CURRENT ACADEMIC TITLE: Professor

ADDRESS:

Business: Division of Public Health Sciences
Wake Forest University School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157-1063
Telephone: (336) 716-3730

EDUCATION:

1956-1958	University of Uppsala Uppsala, Sweden MK (Medicine Kandidat) (undergraduate)
1959-1963	University of Umea Umea, Sweden M.L. (M.D. equivalent)
1968	University of Umea Umea, Sweden Thesis: "Effects of beta-adrenergic blockade on ECG, physical working capacity and central circulation with special reference to autonomic imbalance" (Advisor: Professor H. Linderholm) (Ph.D. - equivalent)

POSTDOCTORAL TRAINING:

1973	ECFMG
1974 - 1976	Biostatistics: Five courses in the Graduate Program (15 credits) National Institutes of Health Bethesda, Maryland
1977	Epidemiology: Two courses in the Graduate Program (5 credits) National Institutes of Health Bethesda, Maryland

POSTDOCTORAL TRAINING (Continued):

1977	Three courses at the 12th Graduate Summer Session in Epidemiology (8 credits) School of Public Health University of Minnesota
------	--

UNIFORMED SERVICE:

1955 - 1972	Military Service in the Swedish Army (15 months) Rank Held: Captain
-------------	---

PROFESSIONAL LICENSURE:

1963	Sweden, #31987
------	----------------

EMPLOYMENT:

2002 - 2011	Senior Advisor to the Dean for Health Services Research and Health Policy Wake Forest University School of Medicine Winston-Salem, North Carolina
-------------	--

2002- 2011	GCRC Research Subject Advocate Advisor Wake Forest University School of Medicine Winston-Salem, North Carolina
------------	--

2002 (Jan.-April)	Senior Visiting Scholar Center for Outcomes and Effectiveness Research Agency for Healthcare Research and Quality Rockville, Maryland
----------------------	--

1999-2002	Director Office of Academic Program Development Wake Forest University Baptist Medical Center Winston-Salem, North Carolina
-----------	--

1989 - 1999	Chairman Department of Public Health Sciences Wake Forest University School of Medicine Winston-Salem, North Carolina
-------------	--

1986 - 1989	Director Center for Prevention Research and Biometry Bowman Gray School of Medicine Winston-Salem, North Carolina
-------------	--

1985 - 1986	Associate Director Clinical Applications and Prevention Program Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
-------------	--

EMPLOYMENT (Continued):

1984 - 1985	Acting Associate Director Clinical Applications and Prevention Program Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1982 - 1984	Deputy Associate Director Clinical Applications and Prevention Program Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1979 - 1985	Chief, Clinical Trials Branch Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1974 - 1979	Visiting Scientist Clinical Trials Branch National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1973 - 1974	Research Fellow Department of Internal Medicine Minneapolis Lipid Research Center - University of Minnesota Minneapolis, Minnesota
1968 - 1974	Chairman Department of Clinical Physiology Central Hospital Boden, Sweden
1967 - 1968	Acting Deputy Chairman Department of Clinical Physiology University Hospital Umea, Sweden
1963 - 1966	Physician Department of Clinical Physiology University Hospital Umea, Sweden

Academic Experience:

1989 - Present	Professor of Public Health Sciences Wake Forest University School of Medicine Winston-Salem, North Carolina
----------------	---

EMPLOYMENT (Continued):

1987 - Present	Adjunct Associate Professor
----------------	-----------------------------

Department of Public Health and Caring Sciences
Uppsala University
Uppsala, Sweden

1986 - 1989
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

1984 - 1987
Clinical Professor
Department of Community and Family Medicine
Georgetown University School of Medicine
Washington, D.C.

1968 - 1986
Associate Professor of Clinical Physiology
University of Umea
Umea, Sweden

Teaching Experience:

1986 - Present
Wake Forest University School of Medicine
Winston-Salem, North Carolina

1984 - 1986
Georgetown University School of Medicine
Washington, D.C.

1981 - 1985
Faculty Appointment
Graduate School of National Institutes of Health
Bethesda, Maryland

1967 - 1968
Acting Professor
Department of Clinical Physiology
University of Umea (3 months)
Umea, Sweden

OTHER PROFESSIONAL ACTIVITIES:

A. RESEARCH ACTIVITIES

1. Principal Investigator

1970 - 1974
Boden Multifactor Primary Prevention Trial

1970 - 1975
World Health Organization
European Ischemic Heart Disease
Register Study (Center 17 Boden)

1987 - 1993
Pravastatin, Lipids and Atherosclerosis in the Carotids
(PLAC-2) Study

1988 - 1995
Cardiovascular Health Study (NHLBI)
Bowman Gray School of Medicine Field Center

RESEARCH ACTIVITIES (Continued):

1988 - 1994
Asymptomatic Carotid Artery Progression Study (NHLBI)

1989 - 1992	Prevention of Functional Deterioration in Hospitalized Elderly - PREHAB (John A. Hartford Foundation)
1990 - 1992	Urinary Incontinence in Community-Dwelling Women (WFUSM Subcontract)
1992 - 1999	Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial - PREVENT (Pfizer)
1992 -1999	Women's Health Initiative - Clinical Facilities Center (WFUSM Subcontract)
1999 - 2006	Ginkgo Evaluation Memory Study (GEMS) Clinical Coordinating Center

2. Scientific Project Officer, NHLBI

1974 - 1980	Aspirin Myocardial Infarction Study
1976 - 1985	Multiple Risk Factor Intervention Trial
1977 - 1985	Beta-blocker Heart Attack Trial
1980 - 1985	Systolic Hypertension in the Elderly Program
1982 - 1984	Hypertension Prevention Trial
1982 - 1984	Cardiac Arrhythmia Pilot Study
1983 - 1985	Program on Surgical Control of the Hyperlipidemias
1984	Studies of Left Ventricular Dysfunction
1984 - 1985	Preventive Cardiology Academic Awardees Program

3. Data & Safety Monitoring Committees

1975 - 1979	Aspirin Myocardial Infarction Study
1978 - 1982	Beta-blocker Heart Attack Trial
1980 - 1985	Systolic Hypertension in the Elderly Program
1981 - 1982	Multiple Risk Factor Intervention Trial
1982 - 1985	Hypertension Prevention Trial
1983 - 1993	Diabetes Control and Complications Trial
1983 - 1985	Program on Surgical Control of the Hyperlipidemias
1985 - 1987	Prevention of Atherosclerotic Complications with Ketanserin
1986 - 1989	Digibind Post-Marketing Surveillance Study
1986 - 1994	Fluorouracil Filtering Surgery Study (Chairman)
1987 - 1988	Tolrestat Retinopathy Studies (Chairman)
1987 - 1988	Ultradol Rheumatoid Arthritis Trial (Chairman)
1987 - 1989	Shock Resuscitation Clinical Trials (Chairman)
1987 - 1988	Cilazapril/Nitrendipine Hypertension Trials
1987 - 2001	Advanced Glaucoma Intervention Study (Chairman)
1988 - 1996	Post Coronary Artery Bypass Graft Studies
1988 - 1990	Glaxo Restenosis and System Project (Chairman)
1988 - 1994	Scandinavian Simvastatin Survival Study
1988 - 1990	Quality of Life in Hypertension Study
1989 - 1996	Cholesterol and Recurrent Events Study
1989 - 1991	CONSENSUS II Study (Chairman)
1989 - 1991	Ethmozine/Encainide PES Study

RESEARCH ACTIVITIES (Continued):

1989 - 1992	Canadian Coronary Atherosclerosis Intervention Trial (Chairman)
1990 - 1992	Post-Angioplasty Restenosis Ketanserin Trial

1990 - 1997	CABG Patch Trial (Chairman)
1991 - 1996	Quinapril Ischemic Event Trial (Chairman)
1991 - 2001	Age-related Eye Diseases Study
1992 - 1993	FLOLAN International Randomized Survival Study
1992 - 1997	Assessment of Treatment with Lisinopril and Survival
1992 - 1998	Randomized Aldactone Efficacy Study
1993 - 1996	Coumadin Aspirin Reinfarction Study
1993 - 1996	WHO Programme for the Prevention of Blindness (Chairman)
1993 - 2001	Early Manifest Glaucoma Trial (Chairman)
1994 - 1996	Evaluation of Losartan in the Elderly (Chairman)
1994 - 1999	Heart Outcomes Prevention Evaluation (HOPE)
1994 - 1997	Accupril Congestive Heart Failure Investigation and Economic Variable Evalaution (ACHIEVE)
1995 - 1997	Myloral in Multiple Sclerosis Trial (Chairman)
1995 - 1998	Trials of Amylin in Diabetes (Amylin)
1997 - 1998	CV-2619/PNRP 001 in Alzheimer's Disease (Takeda America)
1997 - 1999	Effects of Losartan on Mortality in CHF (ELITE II) (Chairman)
1998 - 1999	Melacine plus Interferon versus Interferon in Malignant Melanoma (CATO Research)
1998 - 2001	Adenosine in Acute MI (MEDR640), Chairman (ClinTrials Research)
1998 - 2001	Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL)
1999 - 2002	Eplererone in Heart Failure Post Acute Myocardial Infarction (EPHESUS)
1999 - 2002	Lung Health Study
2000 - Present	Selenium and Vitamin E Chemoprevention Trial (SELECT) (Southwest Oncology Group)
2000 - 2003	Heart Outcomes Prevention Evaluation II
2001 - 2006	Periodontal Intervention for Cardiac Events
2002 - 2005	Pilot Trial of Etanercept in IPF (Chairman)
2003 – Present	Pepper Center Data Safety and Monitoring Committee (Chairman)
2004 - 2009	INO Therapeutics Trials (Chairman)
2007 - Present	Glioblastoma Trial (Northwest Biotherapeutics; Chairman)
2007 - 2008	PLA-695 for pain control (Wyeth) (Chairman)
2007 - 2008	Biogen trials in Parkinson's Disease
2007 - 2008	Mini-Metrics phase II trial
2008 - Present	Institutional Data and Safety Monitoring Committee (Chairman)

B. LEADERSHIP

1. Steering/Investigators Committee

1988 - 1994	Chair, Steering Committee of the Multicenter Isradipine Diuretic Atherosclerosis Study Sandoz Research Institute
1989 - Present	Chair, Steering Committee of the Cardiovascular Health Study National Heart, Lung, and Blood Institute

LEADERSHIP (Continued):

1992 - 2002	Chair, Investigators Committee of the Heart, Estrogen- Progestin Replacement Study Wyeth-Ayerst
-------------	---

1992 - 1999	Co-Chair, Steering Committee of Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial Pfizer Laboratories
1992 - 2005	Chair, Prospective Pravastatin Pooling Project Bristol-Myers Squibb
1993 - 1995	Chair, Executive Committee
1993 - 1996	Chair, Publications & Presentations Subcommittee
1993 - 1995	Member, Management Committee
1995 - 1998	Performance Monitoring Committee Women's Health Initiative National Institutes of Health
1993 - 2004	Chair, Steering Committee of the Antihypertensive Lipid-Lowering to prevent Heart Attack Trial National Heart, Lung, and Blood Institute
1999 - 2010	Chair, Steering Committee of Ginkgo Evaluation Memory Study National Heart, Lung, and Blood Institute

2. Professional Organizations

1982 - 1984	Member and Chairman, Program Committee, Society for Clinical Trials
1984 - 1988	Secretary, Society for Clinical Trials
1992 - 1993	President, Society for Clinical Trials
1993 - 1994	Past President Society for Clinical Trials
1992 - 1994	Member, Public Affairs Policy Committee American Heart Association Dallas, Texas
1992 - 1995	Member, Long Range Planning Committee Council for Epidemiology and Prevention American Heart Association
1994 - 1998	Member, Advisory Board of Controlled Clinical Trials
1999 - 2005	Member, Executive Council American Society of Hypertension
2004 - 2005	Member, CME Committee American Society of Hypertension
2008 - Present	Secretary, American Journal of Hypertension

LEADERSHIP (Continued):

3. Intramural Committees

1989 - 1996	Acting Director, Nutrition Center Bowman Gray School of Medicine Winston-Salem, North Carolina
-------------	--

2008 – Present

Translational Science Institute Drug Safety Newsletter (Editor)

C. EXTRAMURAL ACTIVITIES

1. Government

1983 - 1985	Bilateral Exchange Program West Germany (NHLBI)
1984 - 1985	Equal Employment Opportunity Committee National Heart, Lung, and Blood Institute
1984 - 1985	Training Committee National Heart, Lung, and Blood Institute
1984 - 1985	Working Group to Revise Statement on Hypertension in the Elderly National Heart, Lung, and Blood Institute
1989 - 1991	Member
1991 - 1993	Chairman Clinical Applications and Prevention Advisory Committee National Heart, Lung, and Blood Institute
1992 - 1993	Member, NIDDK Planning Committee
1992 - 1993	Chair, NHLBI Planning Committee NIDDM Clinical Trial
1992 - 1993	Member, Task Force on Research in Epidemiology and Prevention of CVD National Heart, Lung, and Blood Institute
2001- 2003	Medicaid Drug Utilization Review North Carolina Department of Health and Human Services
2001- 2006	Member, Drug Safety and Risk Management Subcommittee of the Pharmaceutical Science Advisory Board Food and Drug Administration
2007- 2010	Ad hoc Reviewer Food and Drug Administration
2010 -	Member, Comparative Effectiveness Committee, North Carolina General Assembly

EXTRAMURAL ACTIVITIES (Continued):

2. Editorial Boards

1983 - 1986, 2001 - 2008	Circulation
1983 - 1987	Controlled Clinical Trials
1987 - 1990	Cardiovascular Drugs and Therapy
1988 - 1995	Journal of Drug Development
1989 - 1998	Journal of Internal Medicine
1990 - 1997	Annals of Epidemiology
1991 - 1997	Cardiology in the Elderly
1992 - 1997	American Journal of Geriatric Cardiology
1996 - 2006	Evidence-Based Cardiovascular Medicine
1996 - 2005	American Heart Journal
1999 - 2005	Current Controlled Trials in Cardiovascular Medicine (Editor)
2001 - 2003	Fundamental and Clinical Pharmacology (Field Editor)
2001 - 2003	Cardiovascular Diabetology
2004 - 2006	Current Cardiology Reviews
2006 - Present	TRIALS
2007 - 2008	Journal of Medical Case Reports
2008 - Present	QuarterWatch (Institute for Safe Medication Practices)

3. Consultations

1971 - 1972	Temporary Advisor WHO's Working Group on IHD Registers Copenhagen, Denmark
1973	Temporary Advisor WHO's Working Group of Methodology Multicenter Preventive Trials in IHD Innsbruck, Austria
1982 - 1984	Professional Postgraduate Services New York, New York
1982 - 1985	Food and Drug Administration
1983 - 1987	Temporary Advisor, WHO
1988 - 1990	International Cardiovascular Advisory Committee, Glaxo
1991 - 1993	University of Wisconsin Clinical Cancer Center Advisory Committee
2005, 2007-2009	Temporary Advisor, WHO

4. Professional Memberships

American Heart Association
American Heart Association Council of
Epidemiology
International Society and Federation of
Cardiology

EXTRAMURAL ACTIVITIES (Continued):

Society for Clinical Trials
American Society of Hypertension

D. ADMINISTRATIVE ACTIVITIES

1. Intramural

1986 - 1992	Acting Associate Director of Cancer Control WFU Cancer Center Bowman Gray School of Medicine
1988 - 1989	Chair
1989 - 1993	Member , General Clinical Research Center Committee Bowman Gray School of Medicine
1990 - 1994	Co-chair, Executive Committee Target Health Bowman Gray School of Medicine
1992 - 1994	Co-chair, Medical Center Health Services Steering Committee Bowman Gray School of Medicine
1992 - 1993	Chair, Dean's Ad hoc Committee for Co-recruitment and Program Coordination
1994	Member, Planning Committee for Institutional Research Retreat
2000 - Present	Member, Pharmacy and Therapeutics Committee
2002 - 2008	Member, GCRC Human Subject Protection Committee
2003 - 2009	Chair, Genomics Center Oversight Committee
2003 - 2010	Chair, Cancer Center Oversight Committee
2003 - Present	Chair, Outpatient Prescription Drug Subcommittee
2007 - Present	Member, Conflict-of-Interest Review Committee
2007 – 2008	Chair, Informatics Committee
2008 – 2010	Chair, TSI Council
2008 – 2009	Chair, Industry Relations Committee

ADMINISTRATIVE ACTIVITIES (continued):

2. Search Committees

1981	Chair, Search Committee for Chief, Preventive Cardiology Branch National Heart, Lung, and Blood Institute
1982	Chair, Search Committee for Chief, Mathematical and Applied Statistics Branch National Heart, Lung, and Blood Institute
1987 - 1998	Member, Chair Internal Medicine Chair, Head Section of General Internal Medicine Member, Head Section of Cardiology Member, Director of WFU Comprehensive Cancer Center Chair, Associate Dean for Research Director, Nutrition Center

E. HONORS AND AWARDS

1983	Director's Award - National Institutes of Health
1998	Women's Health Initiative Achievement Award - NHLBI
2001	Established Investigator in Clinical Science Award - Wake Forest University
2002	Ancel Keys Lecture Award - American Heart Association
2004	Joseph Stokes, III Award - American Society of Preventive Cardiology
2004	Doctor Honoris Causa - Umeå University
2004	The Rockefeller Foundation Residency Award, Bellagio, Italy
2005	Fellow of the Society for Clinical Trials
2007	Healthcare Heroes Award - The Business Journal

BIBLIOGRAPHY:

Monographs and Textbooks:

Furberg C. Effects of beta-adrenergic blockade on ECG, physical working capacity and central circulation with special reference to autonomic imbalance. *Acta Med Scand* 1968; (suppl 488).

Braunwald E, Friedewald WT, Furberg CD, eds. Proceedings of the workshop on platelet-active drugs in the secondary prevention of cardiovascular events. *Circulation* 1980;62(suppl V).

Friedman LM, Furberg CD, DeMets DL. *Fundamentals of clinical trials*, 1st ed. Boston: John Wright, 1981.

Furberg CD, Friedewald WT, Eberlein KA, eds. Proceedings of the workshop on implications of recent beta-blocker trials for post-myocardial infarction patients. *Circulation* 1983;67(suppl I).

Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. *Assessment of quality of life in clinical trials of cardiovascular therapies*. New York: LeJacq, 1984.

Friedman LM, Furberg CD, DeMets DL. *Fundamentals of clinical trials*, 2nd ed. Littleton: PSG Publishing Company, 1985.

Wenger NK, Furberg CD, Pitt E, eds. *Coronary heart disease in the elderly*. New York: Elsevier, 1986.

Furberg B, Furberg C. *All that glitters is not gold. What clinicians need to know about clinical trials*. North Carolina: Jostens, 1994.

Friedman LM, Furberg CD, DeMets DL. *Fundamentals of clinical trials*, 3rd ed. St. Louis: Mosby, 1996; New York: Springer-Verlag, 1998.

Aaserud M, Dahlgren AT, Sturm H, Kösters JP, Hill S, Furberg CD, Grilli R, Henry DA, Oxman AD, Ramsay C, Ross-Degnan D, Soumerai SB. Pharmaceutical policies: effects on rational drug use. *The Cochrane Database of Systematic Reviews* 2004, Issue 2. DOI:10.1002/14651858.CD004397.

DeMets DL, Furberg CD, Friedman LM, eds. *Data monitoring in clinical trials. A case studies approach*. New York: Springer, 2006.

Furberg BD, Furberg CD. *Evaluating clinical research. All that glitters is not gold*, 2nd ed. New York: Springer, 2007.

Friedman LM, Furberg CD, DeMets DL. *Fundamentals of clinical trials*, 4th ed. New York: Springer, 2010.

Furberg CD, Furberg BD, Sasich LD. *Knowing your medications: A guide to becoming an informed patient*. E-book, 2010.

Chapters in Books:

Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Lipoprotein pattern in IHD. In: Tibblin G, Keys A, Werko L, eds. *Preventive cardiology*. Stockholm: Almqvist & Wiksell, 1972:166-170.

Lundkvist L, Furberg C, Svardsudd K. Special problems concerning myocardial infarction in Northern Sweden (Norrbotten). In: Bylund E, Linderholm H, Rune O, eds. *Ecological problems of the Circumpolar Area*. Lulea: Norrbottens Museum, 1974:202-207.

Svardsudd K, Furberg C, Lundkvist L. Latent need of medical service in Northern Sweden (Norrbotten) with special reference to cardiovascular diseases. In: Bylund E, Linderholm H, Rune O, eds. *Ecological problems of the Circumpolar Area*. Lulea: Norrbottens Museum, 1974:209-211.

BIBLIOGRAPHY: (Chapters in Books Continued):

Berg K, Dahlen G, Erikson C, Frick H, Furberg CD, Wiljasalo M. Pre-beta lipoprotein: relationship to angiographically proven coronary heart disease and to Lp(a) lipoprotein. In: Schettler G, Weizel A, eds. *Atherosclerosis III: proceedings of the Third International Symposium*. New York: Springer-Verlag, 1974:481-487.

Furberg CD. Possible yields of various forms of interventions after myocardial infarction. In: Hjalmarson A, Wilhelmsen L, eds. *Acute and long-term management of myocardial ischemia*. Molndal: Lindgren & Soner, 1978:309-311.

Furberg CD, Friedewald WT. The effects of chronic administration of beta-blockade on long-term survival following myocardial infarction. In: Braunwald E, ed. *Beta-adrenergic blockade: a new era in cardiovascular medicine*. New York: Excerpta Medica, 1978:171-177.

Furberg CD. The role of beta-blockers in cardioprotection. In: Laragh JH, Buhler FR, Seldin DW, eds. *Frontiers in hypertension research*. New York: Springer-Verlag, 1981:495-499.

Furberg CD. Who should fund clinical trials? In: Morganroth J, Moore EN, eds. *The evaluation of beta blocker and calcium antagonist drugs*. Boston: Nijhoff, 1982:262-264.

Furberg CD, May GS, Eberlein KA, Passamani ER, Demets DL. Secondary trials after myocardial infarction: a review. In: Hauss WH, Wissler RW, eds. *Second Munster International Arteriosclerosis Symposium: clinical implications of recent research results in arteriosclerosis*. Abhandlung der Rheinisch-Westfalischen Akademie der Wissenschaften, Band 70 1983:39-58.

Furberg CD, May GS. Secondary prevention of myocardial infarction. In: Turner P, Shand DG, eds. *Recent advances in clinical pharmacology*. New York: Churchill Livingstone, 1983:207-221.

Furberg CD. Beta-Blocker Heart Attack Trial. In: Robertson JIS, Kaplan NM, Caldwell ADS, Speight TM, eds. *International symposium on beta blockade in the 1980s: focus on atenolol*. *Drugs* 1983;25(suppl 2):314-317.

Furberg CD. Additional data from the Beta Blocker Heart Attack Trial (BHAT). In: Shand DG. *New Perspectives on Beta Blockers in Patients with Acute Myocardial Infarction: Proceedings of a Symposium*. MEDED Publishers, Inc., Miami, FL, 1983:19-26.

Furberg CD, Mattson ME. Bestimmung der Lebensqualität in Klinischen Studien. In: Rohde H, Troidl H, eds. *Das Magenkarzinom: Methodik Klinischer Studien und Therapeutischer Ansätze*. Stuttgart: G. Thieme, 1984:57-61. [Ger]

Furberg CD, Mattson ME. Kriterien für die Auswahl von Untersuchern, Datenqualität und Datenüberwachung bei Multizentrischen Studien. In: Rohde H, Troidl H, eds. *Das Magenkarzinom: Methodik Klinischer Studien und Therapeutischer Ansätze*. Stuttgart: G. Thieme 1984:9-12. [Ger]

Levy RI, Furberg CD, Rifkind BM. Primary prevention of coronary artery disease. In: Petersdorf RG, et al., eds. *Harrison's principles of internal medicine*. Update V. New York: McGraw-Hill, 1984:47-65.

Furberg CD, Schucker B, Chesney MA, et al. Report of the working group: mild hypertension. In: Wenger NK, Mattson ME, Furberg CD, Elinson J., eds. *Assessment of quality of life in clinical trials of cardiovascular therapies*. New York: LeJacq, 1984:285-295.

Frishman WH, Charlap S, Rotmensch HH, Furberg CD. Beta-adrenergic blockade in patients with myocardial infarction: treatment and prevention. In: Frishman WH, ed. *Clinical pharmacology of the beta-adrenoceptor blocking drugs*. Norwalk: Appleton-Century-Crofts, 1984:299-340.

Friedewald WT, Furberg CD. Clinical trials of modification of mortality during acute myocardial infarction. In: Califf RM, Wagner GS, eds. *Acute coronary care: principles and practice*. Boston: Nijhoff, 1985:145-155.

BIBLIOGRAPHY: (Chapters in Books Continued):

Frommer PL, Furberg C. Beta-blocking drugs in the prevention of sudden cardiac death. In: Morganroth J, Horowitz LN, eds. Sudden cardiac death. Orlando: Grune & Stratton, 1985:249-256.

Frishman WH, Laifer LI, Furberg CD. Beta-adrenergic blockers in the prevention of sudden death. In: Morganroth J, Horowitz LN, eds. Sudden cardiac death. Orlando: Grune & Stratton, 1985:249-264.

Frommer PL, Furberg CD. The role of beta-blockers in the prevention of sudden cardiac death in the postinfarction patient. In: El-Sherif N, Reddy CVR, eds. The pathophysiology and pharmacotherapy of myocardial infarction. Orlando: Academic Press, 1986:347-369.

Shephard RJ, Wenger NK, Furberg CD, et al. Education of the aged cardiac patient. In: Wenger NK, ed. The education of the patient with cardiac disease in the twenty-first century. New York: LeJacq, 1986:406-409.

Cutler JA, Furberg CD. Prevention of stroke: evidence from clinical trials. In: Fidge NH, Nestel PG, eds. Atherosclerosis VII. Amsterdam: Excerpta Medica, 1986:587-591.

Furberg CD, Cutler JA, Probstfield JL, Page L, Hulley SB. The systolic hypertension in the elderly program. In: Strasser T, Ganten D, eds. Mild hypertension: from drug trials to practice. New York: Raven, 1987:59-63.

Furberg CD. Trials of beta-blocker therapy in myocardial infarction. In: Roberts R, ed. Current perspectives in coronary care: selected proceedings of two symposia: Bermuda, August 14-17, 1986, San Diego, August 22-25, 1986. Princeton: Excerpta Medica, 1987:23-30.

Yusuf S, Furberg CD. Single factor trials: control through life-style changes. In: Olsson AG, ed. Atherosclerosis: biology and clinical science. Edinburgh: Churchill Livingstone, 1987:389-391.

Furberg CD, Cutler J. Multiple factor intervention: controlled trials. In: Olsson AG, ed. Atherosclerosis: biology and clinical science. Edinburgh: Churchill Livingstone, 1987:399-401.

Furberg C. What CHF trials have shown to date and what is needed? In: Morganroth J, Moore EN, eds. Congestive heart failure. Boston: Nijhoff, 1987:251-254.

Furberg CD, Cutler JA, MacMahon SW, Yusuf S. Clinical trials in hypertension and congestive heart failure. In: Beamish RE, Panagia V, Dhalla NS, eds. Pharmacological aspects of heart disease: proceedings of an international symposium on heart metabolism in health and disease and the Third Annual Cardiology Symposium of the University of Manitoba, July 8-11, 1986, Winnipeg, Canada. Boston: Nijhoff, 1987:89-95.

MacMahon SW, Furberg CD, Cutler JA. Women as participants in trials of the primary and secondary prevention of cardiovascular disease: Part I. Primary prevention: The hypertension trials. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. Coronary Heart Disease in Women: Proceedings of a Workshop. New York: Haymarket Doyma Inc., 1987:233-240.

Furberg, CD, Friedman LM, MacMahon SW. Women as participants in trials of the primary and secondary prevention of cardiovascular disease. Part II. Secondary prevention: The Beta-Blocker Heart Attack Trial and the Aspirin Myocardial Infarction Study. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. Coronary Heart Disease in Women: Proceedings of a Workshop. New York; Haymarket Doyma Inc., 1987:241-246.

Furberg CD. The secondary prevention trials: lessons learned, questions raised. In: Gorlin, ed. Postgraduate Medicine: A quarter-century of beta blockade. New York; BMI/McGraw-Hill, 1988:83-89.

Furberg CD, Craver DM. Secondary prevention: Life-style interventions. In: Higgins M, Luepker RV, eds. Trends in coronary heart disease mortality: the influence of medical care. NY: Oxford University Press, 1988:227-231.

BIBLIOGRAPHY: (Chapters in Books Continued):

Furberg CD, Cutler JA, MacMahon SW. Principles of clinical trials, with an example from neurologic disease. In: Vinken PJ, Bruyn GW, Klawans HL, eds. *Handbook of Clinical Neurology*. Elsevier Science Publishers, 1988:459-467.

Furberg CD, Byington RP. Beta adrenergic blockers in patients with acute myocardial infarction. In: Pepine CG, ed. *Acute Myocardial Infarction*. Cardiovascular Clinics, Philadelphia, PA, 1989:235-248.

Byington RP, Furberg CD. Beta-blockers during and after acute myocardial infarction. In: Francis GS, ed. *Modern Coronary Care*. Little Brown and Co. Publishers, Boston MA, 1989:511-539.

Furberg CD. Therapy for heart failure: implications for improved survival. In: Sonnenblick, Laragh, Lesch, ed. *ACE inhibition: From mechanism to therapy*. Excerpta Medica, Princeton, NJ, 1989:218-224.

Furberg CD. Impact of clinical trials on clinical practice. In: Wolff, Fleckenstein, Philipp, eds. *Drug Research and Drug Development in the 21st Century*. *Arzneim-Forsch/Drug Res*. 1989:39(II):986-988.

Furberg CD. What do new cardiovascular agents (e.g. antiarrhythmic drugs) have to show to establish a favorable risk versus benefit ratio to obtain approvability? - Clinical viewpoint. In Morganroth J, ed. *Ninth Annual Proceedings, Symposium on New Drugs and Devices*, Philadelphia, PA, 1989:153-156.

Furberg CD, Byington RP, Espeland M. Should a change in the atherosclerotic process be required for approval of new hypolipidemic agents. In Morganroth J, ed. *Ninth Annual Proceedings, Symposium on New Drugs and Devices*, Philadelphia, PA, 1989:233-239.

Probstfield JL, Applegate WB, Curb JD, Borhani NO, Hawkins CM, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page LB, Perry HM, Smith WM. The Systolic Hypertension in the Elderly Program (SHEP): Rationale, Design, Recruitment, and Baseline Data. In: Omae T, Zanchetti A, eds. *How should elderly hypertensive patients be treated?* Springer-Verlag, Tokyo, 1989:135-142.

Wenger NK, Furberg CD. Cardiovascular Disorders. In: Spilker B, ed. *Quality of Life Assessments in Clinical Trials*. Raven Press, 1990:335-345.

Probstfield JL, Furberg CD. Systolic hypertension in the elderly: Controlled or uncontrolled. In: Frohlich ED, ed. *Cardiovascular Clinics*. Philadelphia: F. A. Davis Co. 1990:65-84.

Byington RP, Worthy J, Craven T, Furberg CD. Beta-Blockers after a myocardial infarction: Do their effects on blood lipids counteract the favorable effects of beta-blockade? In: Ischinger T, Gohlke H, eds. *Strategies in Primary and Secondary Prevention of Coronary Artery Disease*. W. Zuckschwerdt Verlag, 1992:113-131.

Cutler JA, Furberg CD. The clinical trials: a selective review. In: Lenfant C, Roccella E, eds. *National High Blood Pressure Program -- 20 years of achievement*. National Heart, Lung, and Blood Institute, Bethesda. 1992:79-86.

Manolio TA, Furberg CD. Epidemiology of sudden cardiac death. In: Myerburg RJ, Akhtar M, Ruskin J, eds. *Sudden Cardiac Death*. Wayne, PA: Andover Medical Publishers, Inc. 1994:3-20.

Psaty BM, Furberg CD. Treatment trials: morbidity and mortality. In: Black H, Izzo JL, eds. *Hypertension Primer*. 1993:192-201.

Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control. What has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. *Hypertension, Physiology, Diagnosis, and Management*, Second Edition. Raven Press, Ltd., New York, 1995.

BIBLIOGRAPHY: (Chapters in Books Continued):

- Furberg CD, Byington RP, Riley W. B-Mode ultrasonography: A noninvasive method for assessing atherosclerosis. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine . Churchill Livingstone, New York, 1995.
- Byington RP, Furberg CD. Beta blockers during and after acute myocardial infarction. In: Francis GS and Alpert, JS, eds. Coronary Care (2nd Edition). Little Brown and Company, Boston, MA, 1995.
- Furberg CD, Manolio TA. Cardiovascular disease in the elderly. In: Yusuf S, Wilhelmsen L. eds. Advanced Issues in Prevention and Treatment of Atherosclerosis. Warwick Printing Company Ltd, United Kingdom, 1996, pp.27-35
- Furberg CD, Psaty BM, Cutler JA. Blood pressure and cardiovascular disease. In: Yusuf S, ed. Evidence Based Cardiology. BMJ Books, London, 1998:226-238.
- Psaty BM, Furberg CD. Treatment trials: morbidity and mortality. In: Black H, Izzo JL, eds. Hypertension Primer, 2nd Edition, 1998.
- Crouse JR, Furberg CD, Byington RP, Riley W. B-mode ultrasound: A noninvasive method for assessing atherosclerosis. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine (2nd Edition). Churchill Livingstone, New York, 2000.
- Cutler JA, Gordon DJ, Davis BR, Wright Jr. JT, Furberg CD. Rationale and design for the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). In: Black HR, ed. Clinical Trials in Hypertension. Marcel Dekker, Inc. 2001.
- DiBari M, Furberg CD, Psaty BM, Applegate WB, Pahor M. Chapter 40. Hypertension. In: Hazzard WR, Blass JP, Halter JB, Ouslander JG, Tinetti ME, eds. Principles of Geriatric Medicine and Gerontology, 5th Edition, McGraw-Hill, 2003.
- Psaty BM, Furberg CD. Treatment trials: morbidity and mortality data: In: Black H, Izzo JL, eds. Hypertension Primer, 3rd Edition, 2002.
- Furberg CD, Psaty BM. Blood pressure and cardiovascular disease. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence Based Cardiology. BMJ Books, London, 2003:146-160.
- Byington RP, Curt D. Furberg. "Mega-trials: The Prospective Pravastatin Pooling (PPP) Project and the Heart Protection Study (HPS)." In Statins-The HMG-CoA Reductase Inhibitors in Perspective. 2nd edition, edited by Gaw A, Packard CJ, Shepherd J. Martin Dunitz, London, 2004: 152-174.
- Crouse JR, Furberg CD, Espeland MA, Riley WA. B-mode ultrasound: A noninvasive method for assessing atherosclerosis. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine (3rd Edition). 2005.
- Moore TJ, Cohen MR, Furberg CD. Strong safety signal seen for new varenicline risks. Executive Summary. Institute for Safe Medication Practices 2008. <http://www.ismp.org/docs/vareniclinestudy.asp>.
- Moore TJ, Cohen MR, Furberg CD. Quarter Watch: 2008 Quarter 1. Executive Summary. Institute for Safe Medication Practices. October 23, 2008 <http://www.ismp.org/quarterwatch/2008Q1.pdf>.

Journal Articles

- Furberg C, Ringqvist T. Effekt av penicillin på fysisk arbetsformaga och upplevelsen av trötthet under arbete. Sven Laekartidn 1963;60:2650-2656. [Swe]
- Holmlund D, Furberg C. Untersuchungen zur wirkung von papaverin auf den gestauten ureter. Z Urol 1964;57:633-637. [Ger]

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg C, Koch G, Ostlund H. Die wirkung einer ganglienblockierenden substanz auf die orthostatische reaktion und die körperliche leistungsfähigkeit in liegender und sitzender stellung beim normalen. *Aerztl Forsch* 1966;20:305-307. [Ger]

Furberg C, Tengblad CF. Adrenergic beta-receptor blockade and the effect of hyperventilation on the electrocardiogram. *Scand J Clin & Lab Invest* 1966;18:467-472.

Furberg C. Adrenergisk beta-receptor-blockad vid EKG-diagnostik i samband med arbetsprov. *Sven Laekartidn* 1966;63:3349-3354. [Swe]

Furberg C. Adrenergic beta-blockade and electrocardiographical ST-T changes. *Acta Med Scand* 1967;181:21-32.

Furberg C. Adrenergic beta-receptor and the relationship between physical working capacity, heart volume and the total amount of hemoglobin. *Scand J Clin Lab Invest* 1967;19:164-170.

Arvedson O, Furberg C, Linderholm H. The effect of a ganglionic blocking agent (chlorisondamine) on electrocardiogram, physical working capacity and hemodynamics in patients with vasoregulatory asthenia. *Acta Med Scand* 1967;182(suppl 472):36-53.

Bergman F, Furberg C. Adrenergic beta-receptor blockade and ECG changes of organic origin. *Scand J Clin Lab Invest* 1967;19:274-279.

Furberg C, Jacobsson KA. Propranolol and angina pectoris: an analysis of the different responses to the drug in patients with angina pectoris. *Acta Med Scand* 1967;181:729-736.

Furberg C. Adrenergic beta-blockade and physical working capacity. *Acta Med Scand* 1967;182:119-127.

Astrand I, Furberg C, et al. The "Minnesota code" for ECG classification: adaptation to CR leads and modification of the code for ECGs recorded during and after exercise. *Acta Med Scand* 1967;183(suppl 481):1-25.

Furberg C. Effects of repeated work tests and adrenergic beta-blockade on electrocardiographic ST and T changes. *Acta Med Scand* 1968;183:153-161.

Furberg C, Schmalensee G. Beta-adrenergic blockade and central circulation during exercise in sitting position in healthy subjects. *Acta Physiol Scand* 1968;73:435-446.

Furberg C, Linderholm H. Effects of hyperventilation on ECG in patients with circulatory disturbances. *Acta Med Scand* 1969;185:167-174.

Furberg C, Morsing C. Adrenergic beta-receptor blockade in neurocirculatory asthenia: a clinical trial of a new beta-receptor blocking agent with special reference to prognosis of therapeutic effect. *Pharmacol Clin* 1969;1:168-171.

Furberg CD, Michaelson G. Effect of Aptin, a beta-adrenergic blocking agent, in arterial hypertension. *Acta Med Scand* 1969;186:447-450.

Furberg C. EKG-diagnostik av funktionella ST-och T-sänkningar. *Opusc Med* 1969;14:356-358. [Swe]

Furberg C, Lundkvist L, Svardsudd K. Preventiv kardiologisk verksamhet i Norrbotten. *Sven Laekartidn* 1972;62:143-146. [Swe]

Dahlen G, Ericson C, Furberg C. Electrophoresis of lipoproteins on cellulose acetate membrane. *Acta Med Scand* 1972;192(suppl 531):5-9.

BIBLIOGRAPHY: (Journal Articles Continued):

- Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Angina of effort and an extra pre-beta lipoprotein fraction. *Acta Med Scand* 1972;192(suppl 531):11-15.
- Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Familial occurrence of an extra pre-beta lipoprotein fraction. *Acta Med Scand* 1972;192(suppl 531):17-21.
- Dahlen G, Ericson C, Furberg C. Variations in pre-beta lipoproteins after a test meal. *Acta Med Scand* 1972;192(suppl 531):21-24.
- Dahlen G, Ericson C, Furberg C. Myocardial infarction and an extra pre-beta lipoprotein fraction. *Acta Med Scand* 1972;192(suppl 531):25-29.
- Adolfsson L, Areskog NH, Furberg C, Granath A, Zetterquist S. Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency. *Eur J Clin Pharmacol* 1972;5:37-43.
- Furberg C, Ringqvist I. Achilles reflex time and sympathetic tone. *Ups J Med Sci* 1973;78:89-92.
- Dahlen G, Ericson C, Furberg C. Pre-beta-1 -ett specifikt lipoprotein? *Sven Laekartidn* 1973;70:2149-2150. [Swe]
- Adolfsson L, Areskog NH, Furberg C, Johnsson G. Effects of single doses of alprenolol and two cardioselective beta-blockers (H87/07 and H93/26) on exercise-induced angina pectoris. *Eur J Clin Pharmacol* 1974;7:111-118.
- Furberg CD. Beta-adrenergic receptor blocking drugs in hypertrophic cardiomyopathy, autonomically mediated cardiovascular functional disorders and Fallot's tetralogy. *Drugs* 1974;7:106-117.
- Frick MH, Dahlen G, Furberg C, Ericson C, Wiljasalo M. Serum pre-beta-1-lipoprotein fraction in coronary atherosclerosis. *Acta Med Scand* 1974;195:337-340.
- Furberg C, Hornell H. Familial QT prolongation and risk of sudden death. *Acta Paediatr Scand* 1975;64:777-782.
- Zetterquist S, Furberg C, Ringqvist I, Soderholm B. Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris. *Curr Ther Res* 1975;17:139-148.
- Boberg J, Boberg M, Furberg C, Isacsson SQ. "Lipid Research Clinics" - nytt begrepp i klinisk atherosclerosforskning. *Sven Laekartidn* 1975;72:2517-2521. [Swe]
- Furberg C, Isacsson SO. Rokstopp ger forlangt liv! *Sven Laekartidn* 1975;72:2936-2938. [Swe]
- Furberg C, Heinrich G, Hallen J, et al. Lang Q-T syndromet. *Sven Laekartidn* 1975;72:4620-4625. [Swe]
- Furberg CD, Romo M, Linko E, Siltanen P, Tibblin G, Wilhelmsen L. Sudden coronary death in Scandinavia: a report from Scandinavian coronary heart disease registers. *Acta Med Scand* 1977;201:553-557.
- Isacsson SO, Borgstrom B, Lindgren G, Furberg C, Hovstradius S, Lundkvist B. Naringsintag och kostvanor hos 58- ariga man. *Naeringsforskning* 1978;22:11-16. [Swe]
- Aspirin Myocardial Infarction Study Research Group. A randomized controlled clinical trial of aspirin in persons recovered from myocardial infarction. *JAMA* 1980;243:661-669.

BIBLIOGRAPHY: (Journal Articles Continued):

Rautaharju PM, Prineas RJ, Crow RS, Seale D, Furberg C. The effect of modified limb electrode positions on electrocardiographic wave amplitudes. *J Electrocardiol* 1980;13:109-114.

Furberg CD. Principles of clinical trials: US viewpoint. *Triangle* 1980;19:99-102.

May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. *Circulation* 1981;64:669-673.

Beta-Blocker Heart Attack Trial Research Group. Beta-Blocker Heart Attack Trial: design features. *Controlled Clin Trials* 1981;2:275-285.

Beta-Blocker Heart Attack Trial Research Group. How informed is informed consent? The BHAT experience. *Controlled Clin Trials* 1981;2:287-303.

Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. *JAMA* 1982;247:1707-1714.

Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. *JAMA* 1982;248:1465-1477.

Friedewald WT, Furberg CD. Key references: Clinical trials. *Circulation* 1982;65:213-215.

May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. *Prog Cardiovasc Dis* 1982;24:331-352.

May GS, Furberg CD, Eberlein KA, Geraci BJ. Secondary prevention after myocardial infarction: a review of short-term acute phase trials. *Prog Cardiovasc Dis* 1983;25:335-359.

Furberg CD, Bell RL. Effect of beta-blocker therapy on recurrent nonfatal myocardial infarction. *Circulation* 1983;67(suppl I):183-185.

Furberg CD, Byington RP. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. *Circulation* 1983;67(suppl I):I98-I101.

Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: II. Morbidity results. *JAMA* 1983;250:2814-2819.

Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. *Am J Cardiol* 1983;52:32C-36C.

The Coronary Drug Project Research Group. Blood pressure in survivors of myocardial infarction. *J Am Coll Cardiol* 1984;4:1135-1147.

Furberg CD. Clinical value of intracoronary streptokinase. *Am J Cardiol* 1984;53:626-627.

Frishman WH, Furberg CD, Friedewald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. *N Engl J Med* 1984;310:830-837.

Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. *Circulation* 1984;69:761-765.

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg CD, May GS. Effect of long-term prophylactic treatment on survival after myocardial infarction. *Am J Med*

1984;76(6A):76-83.

Wenger NK, Mattson ME, Furberg CD, Elinson J. Assessment of quality of life in clinical trials of cardiovascular therapies. *Am J Cardiol* 1984;54:908-913.

Friedewald WT, Furberg CD, May GS. Aspirin and myocardial infarction. *Cardiovasc Rev & Rep* 1984;5:1285-1289.

Frishman WH, Furberg CD, Friedewald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. *Curr Probl Cardiol* 1984;9:1-50.

The Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. *Am J Cardiol* 1985;55:1-15.

The Multiple Risk Factor Intervention Trial Research Group. Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. *Am J Cardiol* 1985;55:16-24.

Furberg CD, Yusuf S, Thom TJ. Potential for altering the natural history of congestive heart failure: need for large clinical trials. *Am J Cardiol* 1985;55:45A-47A.

Furberg CD, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. *Am J Cardiol* 1985;55:1110-1113.

Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. *Clin Pharmacol Ther* 1985;38:509-518.

Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. *Eur Heart J* 1985;6:556-585.

Hulley SB, Furberg CD, Gurland B, et al. Systolic hypertension in the elderly program (SHEP): antihypertensive efficacy of chlorthalidone. *Am J Cardiol* 1985;56:913-920.

Cutler JA, Furberg CD. Drug treatment trials in hypertension: a review. *Prev Med* 1985;14:499-510.

Furberg CD (for the BHAT Study Group). The Beta-Blocker Heart Attack Trial. *Z Kardiol* 1985;74(suppl 6):159-165.

Yusuf S, Wittes J, Bailey R, Furberg C. Digitalis - a new controversy regarding an old drug: the pitfalls of inappropriate methods. *Circulation* 1986;73:14-18.

Beta-Blocker Heart Attack Trial Research Group. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. *J Am Coll Cardiol* 1986;7:1-8.

Rautaharju PM, Prineas RJ, Eifler WJ, Furberg CD, Neaton JD, Crow RS, Stamler J, Cutler JA. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. *J Am Coll Cardiol* 1986;8:1-10.

MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. *Prog Cardiovasc Dis* 1986;24(suppl 1):99-118.

BIBLIOGRAPHY: (Journal Articles Continued):

Rautaharju PM, Broste SK, Prineas RJ, Eifler WJ, Crow RS, Furberg CD. Quality control procedures for the resting electrocardiogram in the Multiple Risk Factor Intervention Trial. *Controlled Clin Trials* 1986;7:46S-65S.

Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. *Prev Med* 1986;15:254-273.

Crow RS, Rautaharju PM, Prineas RJ, et al. Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at high risk of symptomatic coronary heart disease. *Am J Cardiol* 1986;57:1075-1082.

Smith WM, Feigal DW, Furberg CD, et al. Use of diuretics in treatment of hypertension in the elderly. *Drugs* 1986;31(suppl 4):154-164.

The Working Group on Hypertension in the Elderly. Statement on hypertension in the elderly. *JAMA* 1986;256:70-74.

Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic heart failure. *Adv Cardiol* 1986;34:124-130.

Furberg CD. Overview of completed sudden death trials: US experience. *Cardiology*, 1987;74(suppl 2):24-31.

MacMahon SW, Cutler JA, Neaton JD, Furberg CD, Cohen JD, Kuller LH, Stamler J, for the Multiple Risk Factor Intervention Trial Research Group. Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studies. *J Hypertens* 1986;4(suppl 6):S14-S17.

Perry HM Jr, McDonald RH, Hulley SB, Smith WM, Furberg CD, Greenlick MR, Kuller LH, Schnaper HW, Schoenberger JA, Vogt TM. Systolic hypertension in the elderly program, pilot study (SHEP-PS): morbidity and mortality experience. *J Hypertens* 1986;4(suppl 6):S21-S23.

Furberg CD, Morgan TM. Lessons from overviews of cardiovascular trials. *Stat Med* 1987;6:295-303.

Kostis JB, Byington R, Friedman LM, Goldstein S, Furberg C, for the BHAT Study Group. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. *J Am Coll Cardiol* 1987;10:231-242.

Furberg CD. Secondary prevention trials after acute myocardial infarction. *Am J Cardiol* 1987;60:28A-32A.

Dimsdale JE, Ruberman W, Carleton RA, DeQuattro V, Eaker E, Eliot RS, Furberg CD, Irvin CW Jr, Lown B, Shapiro AP, Shumaker SA. Task force 1: sudden cardiac death: stress and cardiac arrhythmias. *Circulation* 1987;76(suppl I):I-198-I-201.

Costa PI Jr, Krantz DS, Blumenthal JA, Furberg CD, Rosenman RH, Shekelle RB. Task force 2: psychological risk factors in coronary artery disease. *Circulation* 1987;76(suppl I):I-145-I-149.

Shapiro AP, Alderman MH, Clarkson TB, Furberg CD, Jesse MJ, Julius S, Miller RE, Pitt B. Task force 4: behavioral consequences of hypertension and antihypertensive therapy. *Circulation* 1987;76(suppl I):I-101-I-103.

Davis BR, Furberg CD, Williams CB. Survival analysis of adverse effects data in the Beta-Blocker Heart Attack Trial. *Clin Pharmacol Ther* 1987;41:611-615.

Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after myocardial infarction. *Cardiovascular Drugs and Therapy* 1987;1:343-344.

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg CD. Secondary prevention trials after myocardial infarction. *J Cardiovasc Pharm* 1988;12(Suppl. I):S83-S87.

Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis -- A review. *Stroke* 1988;19:423-430.

Furberg CD, Black DM. The Systolic Hypertension in the Elderly pilot Program: Methodological issues. *Eur Heart J* 1988;9:223-227.

Wenger NK, Furberg CD, Pitt E. Coronary heart disease in the elderly: Review of current knowledge and research recommendations. *Clin. Cardiol* 1988;11:262-264.

The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. *J Clin Epidemiol* 1988;41:1197-1208.

Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. *Am J Cardiol* 1988;62:A41-A45.

Furberg CD. Beta blockade during and after acute MI: Which patients will benefit? *Ill Med* 1988;3:2-15.

The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients. *Eur Heart J* 1988;9:8-16.

Furberg CD, Borhani NA, Byington RP. Multicenter Isradipine Diuretic Atherosclerosis Study: Design features. *Am J Med* 1989;86:37-39.

Prough DS, Furberg CD. Nimodipine and the "No-reflow Phenomenon"-Experimental Triumph, Clinical Failure? *Anesthesia and Analgesia*, 1989;68:431-435.

Furberg CD, Hunt JC. The National Heart, Lung, and Blood Institute Workshop on Antihypertensive Drug Treatment - The Benefits, Costs, and Choices. *Hypertension* 1989;13(suppl I):I-1.

Furberg CD. The impact of clinical trials on clinical practice. *Arzneimittel-Forschung/Drug Research* 1989;39:986-988.

Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension. *Hypertension* 1989;13(suppl I):I-36-I-44.

Furberg CD, Cutler JA. Diuretic agents versus beta-blockers - comparison of effects on mortality, stroke, and coronary events. *Hypertension* 1989;13(suppl I):I-I-61.

Furberg CD, Cutler JA. Implications for research. *Hypertension* 1989;13(suppl I):I-171-I-172.

Perry HM, Jr., Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD, Greenlick MR, Kuller LH, Schnaper HW, Schoenberger JA, Vogt TM, Wolf PA, Hulley SB. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. *Stroke* 1989;20:4-13.

Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. *BMJ* 1989;299:1187-1192.

BIBLIOGRAPHY: (Journal Articles Continued):

Levy RI, Blankenhorn D, Davis CE, Gordon DJ, Furberg C, Huttunen J, Levine RJ, Passamani E, Yusuf S. Workshop V Intervention Studies. *Circulation* 1989;80:739-743.

Boissel JP, Blanchard J, Panak E, Peyreux JC, Sacks H. Considerations for the meta-analysis of randomized clinical

trials. Summary of Panel Discussion. *Controlled Clin Trials*. 1989;10:254-281.

Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, Davis BR, Furberg CD, Hawkins CM, Lakatos E, Page LB, Perry HM, Schron E, Smith WM. The Systolic Hypertension in the Elderly Program (SHEP): An intervention trial on isolated systolic hypertension. *Clin. and Exper. Hyper. - Theory and Practice*, 1989;A11:973-989.

Furberg CD. Proposed guidelines for the clinical evaluation of drugs for the treatment of congestive heart failure: a United States viewpoint. *Curr Opin Cardiol* 1989;4(3):547-552.

Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction - The BHAT Experience. *Am J Cardiology*, 1990;65:1287-1291.

Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. *BMJ* 1990;300:902-903.

The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. *JAMA* 1990;263:1795-1801.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;265:3255-3264.

Furberg CD. Organizing Multicenter Trials: Lessons from cardiovascular prevention trials. *Prev Med* 1991;20:158-161.

Fried LP, Borhani NO, Enright P, Furberg CD, et al. The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol* 1991;1:263-276.

Borhani NO, Applegate WB, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page L, Perry HM, Smith WM, Probstfield JL. Systolic Hypertension in the Elderly Program Part I: Rationale and design. *Hypertension* 1991;17:II-2-II-15.

Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, Kirkpatrick CH, Strauss HC, Smith TW. Digoxin immune fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. *J Am Coll Cardiol* 1991;17:590-598.

Margitic SE, Bond MG, Crouse JR, Furberg CD, Probstfield JL. Progression and regression of carotid atherosclerosis in clinical trials. *Arteriosclerosis* 1991;11:443-451.

Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists following myocardial infarction in light of the DAVIT - II and other recent studies. *Am J Cardiol* 1991;67:1295-1297.

Yusuf S, Furberg CD. Are we biased in our approach to treating elderly patients with heart disease? (Editorial) *Am J Cardiol* 1991;68:954-956.

Furberg CD, Yusuf S. Antiarrhythmics and VPD suppression. (Editorial) *Circulation* 1991;84:928-930.

BIBLIOGRAPHY: (Journal Articles Continued):

Manolio TA, Furberg CD. Age as a predictor of outcome: What role does it play? (Editorial) *Am J Med* 1992;92:1-6.

Morgan T, Furberg C. Commentary on "The use of subjective rankings in clinical trials with an application to cardiovascular disease." *Stat Med* 1992;11:443-445.

Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, Tabatznik B, Rautaharju PM for the Cardiovascular Health Study Collaborative Research Group. Major electrocardiographic abnormalities in persons aged 65 years and older (The Cardiovascular Health Study). *Am J Cardiol* 1992;69:1329-1335.

Manolio TA, Furberg CD, Wahl PW, Tracy RP, Borhani NO, Gardin JM, Fried LP, O'Leary DH, Kuller LH for the CHS Collaborative Research Group. Eligibility for cholesterol referral in community-dwelling older adults. The Cardiovascular Health Study. *Ann Intern Med* 1992;116:641-649.

Fletcher AE, Bulpitt CJ, Chase DM, Collins WCJ, Furberg CD, Goggin TK, Hewett AJ, Neiss AM. Quality of life with three antihypertensive treatments: cilazapril, atenolol, nifedipine. *Hypertension* 1992;19:499-507.

Steinberg D, and Workshop Participants. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop. *Circulation* 1992;85:2338-2345.

ACAPS Cooperative Study Group. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). *Controlled Clin Trials* 1992;13:293-314.

Psaty BM, Furberg CD, Kuller LH, Borhani NO, Rautaharju PM, O'Leary DH, Bild DE, Robbins J, Fried LP, Reid C. Isolated systolic hypertension and subclinical cardiovascular disease in the elderly: initial findings from the Cardiovascular Health Study. *JAMA* 1992;268:1287-1291.

Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M, Furberg CD. Pravastatin, lipids, and atherosclerosis in the carotid arteries: Design features of a clinical trial with carotid atherosclerosis outcome. *Controlled Clin Trials* 1992;13:495-506.

Riley WA, Barnes RW, Applegate WB, Dempsey R, Hartwell T, Davis VG, Bond MG, Furberg CD. Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis: The Asymptomatic Carotid Artery Plaque Study (ACAPS). *Stroke* 1992;23:1062-1068.

Wofford JL, Hickey AR, Ettinger WH, Furberg CD. Lack of age-related differences in the clinical presentation of digoxin toxicity. *Arch Intern Med* 1992;152:2261-2264.

Probstfield JL, Byington RP, Egan DA, Espeland MA, Margitic SE, Riley WA, Furberg CD. Methodological issues facing studies of atherosclerotic change. *Circulation* 1993;87(supp II):II-74-II-81.

Furberg CD. Commentary on "Can we measure and predict atherosclerotic progression?" *Circulation* 1993;87(supp II):II-82.

Furberg CD, Borhani NO, Byington RP, Gibbons ME, Sowers JR. Calcium antagonists and atherosclerosis: The Multicenter Isradipine Diuretic Atherosclerosis Study. *Am J Hypertens* 1993;6:24S-29S.

Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth WT, Jr., Weiss NS, Wagner EH, Prentice R, Furberg CD. A review of the association of estrogens and progestins with cardiovascular disease in post-menopausal women. *Arch Intern Med* 1993;153:1421-1427.

BIBLIOGRAPHY: (Journal Articles Continued):

Manolio TA, Furberg CD, Shemanski L, Psaty BM, Bush TL, O'Leary DH, Tracy RP for the CHS Collaborative Research Group. Associations of post-menopausal estrogen use with cardiovascular disease and its risk factors in older women. *Circulation* 1993;88:2163-2171.

Teo KK, Yusuf S, Furberg CD. Effects of prophylactic anti-arrhythmic drug therapy in acute myocardial infarction. An overview of results from the randomized controlled trials. *JAMA* 1993;270:1589-1595.

Schwartz PJ, Bigger JT, Breithardt G, Camm AJ, DeMets DL, Furberg CD, Hallstrom A, Janse MJ, Julian DG, Lan KKG, Lazzara R, Marcus FI, Moss AJ, Tijessen JGP, Waldo AL. The early termination of clinical trials -- causes, consequences, and control -- with special reference to trials in the field of arrhythmias and sudden death. *Circulation* 1994;89:2892-2907.

Zhou SH, Rautaharju PM, Prineas R, Neaton J, Crow R, Calhoun H, Cutler J, Furberg C, Cohen J for the MRFIT Research Group. Improved ECG Models for estimation of LVH progression and regression incidence by redefinition of the criteria for a significant change in LVH status. *J Electrocardiol* 1994;26:108-113.

Furberg CD, Berglund G, Manolio TA, Psaty BM. Overtreatment and undertreatment of hypertension. *J Intern Med* 1994;235:387-397.

Pearce KA, Furberg CD. The primary prevention of hypertension. *Cardiovasc Risk Factors* 1994;4:147-153.

Pearce KA, Furberg CD. Hypertensive cardiovascular disease and the treatment of hypertension in the elderly. *Curr Opin Nephrol Hyper* 1994;3:213-217.

Manolio TA, Furberg CD, Rautaharju PM, Siscovick D, Newman AB, Borhani NO, Gardin JM, Tabatznik B for the CHS Collaborative Research Group. Cardiac arrhythmias on 24-hour ambulatory electrocardiography in older women and men: The Cardiovascular Health Study. *J Amer Coll Cardiol* 1994;15:916-925.

Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. *Am J Epidemiol* 1994;139:1164-1179.

Berglund GL, Riley WA, Barnes RW, Furberg CD. Minisymposium: Ultrasound in clinical trials of atherosclerosis. Quality control in ultrasound studies on atherosclerosis. *J Intern Med* 1994;236:581-586.

Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. *Am J Cardiol* 1994;73:1133-1134.

Furberg CD, Byington RP, Craven TE. Lessons learned from clinical trials with ultrasound endpoints. *J Intern Med* 1994;236:575-580.

Furberg CD, Adams Jr HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B for the Asymptomatic Carotid Artery Plaque Study (ACAPS) Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. *Circulation* 1994;90:1679-1687.

Espeland MA, Hoen H, Byington RP, Howard G, Riley WA, Furberg CD. Spatial distribution of carotid intimal-medial thickness as measured by B-mode ultrasonography. *Stroke* 1994;25:1812-1819.

Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM for the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects: The Cardiovascular Health Study. *Am J Cardiol* 1994;74:236-241.

BIBLIOGRAPHY: (Journal Articles Continued):

Pearson TA, Rapaport E, Criqui M, Furberg C, Fuster V, Hiratzka L, Little W, Ockene I, Williams G. Optimal risk factor management in the patient after coronary revascularization. *Circulation* 1994;90:3125-3133.

Furberg CD. Lipid-lowering trials: results and limitations. *Am Heart J* 1994;128:1304-8.

Furberg CD. Challenges to funding of prevention research. *Prev Med* 1994;23:599-601.

Rautaharju PM, Manolio TA, Psaty BM, Borhani NO, Furberg CD for the CHS Collaborative Research Group. Correlates of QT prolongation in older adults: The Cardiovascular Health Study. *Am J Cardiol* 1994;73:999-1002.

Armstrong PW, Furberg CD. Clinical Trial Data and Safety Monitoring Boards: The search for a constitution. *Circulation* 1995;91:901-904.

Wagenknecht LE, Furberg CD, Hammon JW, Legault, BT Troost. Surgical bleeding: unexpected effect of a calcium antagonist. *BMJ* 1995;310:776-7.

Psaty BM, Koepsell TD, Yanez D, Smith NL, Manolio TA, Heckbert SR, Borhani NO, Gardin JM, Gottdiener J, Rutan GH, Siscovick DS, Furberg CD. Temporal patterns of antihypertensive medication use among older adults, 1989-1992: An effect of the major clinical trials on clinical practice? *JAMA* 1995;273:1436-1438.

Rautaharju PM, Manolio TA, Furberg CD, Siscovick D, Newman AB, Borhani NO, Gardin JM for the CHS Collaborative Research Group. Ischemic episodes in 24-hour ambulatory electrocardiograms of elderly persons: The Cardiovascular Health Study. *Int J Cardiol* 1995;51:165-175.

Adams HP, Byington RP, Hoen H, Dempsey R, Furberg CD for the Asymptomatic Carotid Artery Plaque Study (ACAPS) Research Group. Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. *Cerebrovasc Dis* 1995;5:171-177.

Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: A new look at old data. *Circulation* 1995;91:2274-2282.

Margitic SE, Morgan T, Sager MA, Furberg CD. Lessons learned from a prospective meta-analysis. *J Am Geriatr Soc* 1995;43:435-439.

Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. *Circulation* 1995;92:1326-1331.

Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. *Arch Intern Med* 1995;155:829-837.

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. *Circulation* 1995;92:2419-2425.

Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II): A clinical trial with atherosclerosis outcome. *Am J Cardiol* 1995;75:455-459.

Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? *J Am Geriatr Soc* 1995;43:1309-1310 (Editorial).

Furberg CD, Psaty BM. Should calcium antagonists be first line drugs in hypertension? *Herz* 1995;20:365-369.

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? *Arch Intern Med* 1995;155:2157-2161.

Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. *Arch Fam Med* 1995;4:943-950.

Furberg CD, Pitt B, Byington RP, Park J-S, McGovern ME for the PLAC I and II investigators. Reduction in coronary events during treatment with pravastatin. *Am J Cardiol* 1995;76:60C-63C.

Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive drug therapies: *JAMA* 1995;274:620-625.

Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD for the ACAPS Research Group. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study (ACAPS) *Am J Cardiol* 1995;76:47C-53C.

PPP Project Investigators. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) Project. A combined analysis of three large-scale randomized trials: Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol & Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). *Am J Cardiol* 1995;76:899-905.

Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D for the ACAPS Investigators. Estrogen replacement therapy of progression of intimal-medial thickness in the carotid arteries of postmenopausal women. *Am J Epidemiol* 1995;142:1011-1019.

Byington RP, Furberg CD, Crouse JR, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol* 1995;76:54C-59C.

Ashraf T, Hay J, Pitt B, Wittels E, Crouse J, Davidson M, Furberg C, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. *Am J Cardiol* 1996;76:A3-A7.

O'Leary DH, Polak JF, Kronmal RA, Savage PJ, Borhani NO, Kittner SJ, Tracy R, Gardin JM, Price TR, Furberg CD for the CHS Collaborative Research Group. Thickening of the carotid wall: A marker for atherosclerosis in the elderly? *Stroke* 1996;27:224-231.

Furberg CD, Psaty BM. Calcium antagonists: Not appropriate as first-line antihypertensive agents. *Am J Hypertens* 1996;9:122-125.

Espeland MA, Craven TE, Riley WA, Corson J, Davis VG, Romont A, Furberg CD, for the ACAPS Research Group. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. *Stroke* 1996;27:480-485.

Psaty BM, Siscovick DS, Weiss NS, Koepsell TD, Rosendaal FR, Lin D, Heckbert SR, Wagner EH, Furberg CD. Hypertension and outcomes research: from clinical trials to clinical epidemiology. *Am J Hypertens* 1996;9:178-183.

Furberg CD, Psaty BM. Correction to the nifedipine meta-analysis. *Circulation* 1996;93:1475-1476.

Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal hemorrhage with calcium antagonists in hypertensive persons over 67 years old. *Lancet* 1996;347:1061-1065.

BIBLIOGRAPHY: (Journal Articles Continued):

Legault C, Furberg CD, Wagenknecht LE, Rogers AT, Stump DA, Coker L, Troost BT, Hammon JW. Nimodipine neuroprotection in cardiac valve replacement. Report of an early terminated trial. *Stroke* 1996;27:593-598.

Furberg CD, Hennekens CG, Hulley SB, Manolio T, Psaty BM, Whelton PK. Clinical epidemiology: the conceptual basis for interpreting risk factors. *J Am Coll Cardiol* 1996;27:976-978.

Rautaharju PM, Manolio TA, Siscovick D, Zhou SH, Gardin JM, Furberg CD, Borhani NO, Newman A, for the CHS Collaborative Research Group. Classification accuracy of electrocardiographic criteria for left ventricular

hypertrophy in normalweight and overweight older adults: The Cardiovascular Health Study. *Ann Noninv Electrocardiol* 1996;1:121-132.

Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright, Jr JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial. (ALLHAT) *Am J Hypertens* 1996;9:342-360.

Rosendaal FR, Psaty BM, Furberg CD. Calciumantagonisten: veilig of onveilig? *Ned Tijdschr Geneesk* 1996;140:916-918 (Dutch).

Riley WA, Craven T, Romont A, Furberg CD for the ACAPS Research Group. Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). *Ultrasound Med Biology* 1996;22:405-411.

Rautaharju PM, Manolio RA, Siscovick D, Zhou SH, Gardin JM, Kronmal R, Furberg CD, Borhani NO, Newman A, for the Cardiovascular Health Study Collaborative Research Group. Utility of new electrocardiographic models for left ventricular mass in older adults. *Hypertens* 1996;28:8-15.

Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. *Eur Heart J* 1996;17:1142-1147.

Furberg CD. Aspirin should be used in the primary prevention of coronary heart disease. Pro/Con discussion. *J Coronary Artery Dis Index Reviews*. 1996;11:3,10.

Furberg CD, Psaty BM. Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective. *Cardiovasc Drugs Ther* 1996;10:463-466.

Pahor M, Psaty BM, Furberg CD. Calcium channel blockers: What is their role in the treatment of hypertension in renal patients? *J Nephrology* 1996;9:286-290.

Proschan M, Davis B, Cutler Ford C, Furberg C, Grimm R, Oparil S, for the ALLHAT Research Group. ALLHAT and calcium channel blockers (Letter to the Editor). *Am J Hypertens* 1997;10:142-143.

Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. A review of the health outcomes associated with various anti-hypertensive therapies used as first-line agents. *JAMA* 1997;277:739-745.

Sobel BE, Furberg CD. Surrogates, semantics, and sensible public policy. *Circulation* 1997;95:1661-1663.

Crouse JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. *Arch Intern Med* 1997;157:1305-1310.

Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation* 1997;96:2455-2461.

BIBLIOGRAPHY: (Journal Articles Continued):

Manolio TA, Weinmann GG, Buist AS, Furberg CD, Pinsky JL, Hurd SH. Pulmonary function testing in population-based studies. *Am J Respir Crit Care Med* 1997;156:1004-1010.

Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB, for the PREVENT Investigators. Rationale, design and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). *Am J Cardiol* 1997;80:1087-1090.

Furberg CD, Psaty BM. JNC VI: timing is everything. *Lancet* 1997;350:1413-1414.

Byington RP, Craven TE, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. *Lancet* 1997;350:1075-1076.

Heckbert SR, Longstreth, Jr WT, Psaty BM, Murros KE, Smith NL, Newman AB, Williamson JD, Bernick C, Furberg CD. The association of antihypertensive agents with MRI white matter findings and with modified minimal state examination in older adults. *J Am Geriatr Soc* 1997;45:1423-1433.

Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. *Cancer* 1997;80:1438-47.

Psaty BM, Furberg CD. Clinical implications of the WHO/ISH statement on calcium antagonists. *J Hypertens* 1997;15:1197-1200.

Furberg CD. Drug safety: the different perspectives. *Evidence-based Cardiovascular Medicine* 1998;2:1-2. (Editorial)

World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. *J Hypertens* 16:127-137.

Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: Impact of statin trials. *Circulation* 1998;97:946-952.

Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. *Lancet* 1998;351:689-690.

Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. *JAMA* 1998;279:1571-1573.

Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. *Am J Hypertens* 1998;11:618-629.

Crouse JR, Byington RP, Furberg CD. HMG Co-A reductase inhibitor therapy and stroke reduction: An analysis of clinical trials data. *Atherosclerosis* 1998;138:11-24.

Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart & Estrogen/Progestin Replacement Study (HERS): Design, methods and baseline characteristics. *Controlled Clin Trials* 1998;19:314-335.

Pahor M, Psaty BM, Furberg CD. New evidence on the prevention of cardiovascular events in hypertensive patients with Type 2 diabetes. *J Cardiovasc Pharmacol* 1998;32:S18-S23.

Anderson G, Cummings S, Freedman LS, Furberg C, Henderson M, Johnson SR, Kuller L, Manson J, Oberman A, Prentice RL, Rossouw JE. Design of the Women's Health Initiative Clinical Trial and Observational Study. *Controlled Clin Trials* 1998;19:61-109.

BIBLIOGRAPHY: (Journal Articles Continued):

Lemaitre RN, Psaty BM, Furberg CD, Gordon DJ, Gottdiener JS, Hulley SB, McDonald RH. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study. *Arch Intern Med* 1998;158:1761-1768.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998;280:605-613.

Pahor M, Furberg CD. Calcium antagonists and cancer. Causation or association? *Cardiovasc Drugs Ther.* 1998;12:511-513.

Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. *Drugs & Aging* 1998;13:99-108.

Byington RP, Furberg CD, Craven TE, Pahor M, Sowers JR. Isradipine in pre-diabetic hypertensives. *Diabetes Care* 1998;21:2103-2110.

Furberg CD. Natural statins and stroke risk. *Circulation* 1999;99:185-188.

White RH, McBurnie MA, Manolio T, Furberg CD, Gardin JM, Kittner SJ, Bovill T, Knepper L. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. *Am J Med* 1999;106:165-171.

Smith NL, Psaty BM, Furberg CD, White R, Lima JAC, Newman A, Manolio TA. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. *Arch Intern Med* 1999;159:1574-1578.

Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD. Assessment and control for confounding by indication in observational studies. *J Am Geriatr Soc* 1999;47:749-754.

Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener JS. Traditional risk factors and subclinical-disease measures as predictors of first myocardial infarction in older adults. The Cardiovascular Health Study. *Arch Intern Med* 1999;159:1339-1347.

Byington RP, Evans GW, Espeland MA, Applegate WB, Hunninghake DB, Probstfield J, Furberg CD. Effects of lovastatin and warfarin on early carotid atherosclerosis. Sex-specific analyses. *Circulation* 1999;100:e14-e17.

Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate endpoints, health outcomes and the drug approval process for treatment of risk factors for cardiovascular disease. *JAMA* 1999;282:786-790.

Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. *Lancet* 1999;354:622-625.

Herrington DM, Furberg CD. Hormone therapy: Time for replacement? *Eur Heart J* 1999;20:1285-1286.

Furberg CD, Herrington D, Psaty BM. Class Effects. Are drugs within a class interchangeable? *Lancet* 1999;354:1202-1204.

Furberg CD. Hypertension and diabetes: Current issues. *Am Heart J* 1999;138:S400-S405.

BIBLIOGRAPHY: (Journal Articles Continued):

Psaty BM, Furberg CD. British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity. *BMJ* 1999;319:589-590.

Weber MA, Furberg CD. Comparisons in a competitive world. When is one drug superior to another? *Am J Hypertens* 2000;13:457-459.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2000;283:1967-1975.

Grady D, Wenger N, Herrington D, Khan S, Hulley S, Furberg C, Hunninghake D, Vittinghoff E, for the Heart

Estrogen/progestin Replacement Study (HERS) Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study (HERS). *Ann Intern Med* 2000;132:689-696.

Furberg CD. Class effects and evidence-based medicine. *Clin Cardiol* 2000;23:IV-15-IV-19.

Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. *Diabetes Care* 2000;23:888-892.

Luoto R, Manolio T, Meilahn E, Bhadelia R, Furberg C, Cooper L, Kraut M. Estrogen replacement therapy and MRI-demonstrated cerebral infarcts, white matter changes and brain atrophy in elderly women: The Cardiovascular Health Study. *J Amer Geriatr Soc* 2000;48:467-472.

Psaty BM, Furberg CD, Pahor M, Alderman M, Kuller L. National guidelines, clinical trials and quality of evidence. *Arch Intern Med* 2000;160:2577-2580.

Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller M, Riley W for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation* 2000;102:1503-1510.

Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins M, Keech A, Packard C, Simes J, Byington R, Furberg CD for the Prospective Pravastatin Pooling Project Investigators Group. Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors. The Prospective Pravastatin Pooling Project. *Circulation* 2000;102:1893-1900.

Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuck GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on progression of coronary artery atherosclerosis. *N Engl J Med* 2000;343:522-529.

Knappertz VA, Tegeler CH, Furberg CD, Wesley DJ, Stewart KP, Kitzman DW. Carotid doppler high intensity transient signals in dilated cardiomyopathy. *Am Heart J* 2000;140:44.

Psaty BM, Rhoads C, Furberg CD. Evidence-based medicine, the worship of form, and the treatment of high blood pressure. *J Gen Intern Med* 2000;15:755-756.

Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. *Lancet* 2000;356:1949-1954.

Crouse, III, JR, Furberg CD. Treatment of dyslipidemia: room for improvement? *Arterioscler Thromb Vasc Biol* 2000;20:2333-2335.

BIBLIOGRAPHY: (Journal Articles Continued):

Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, Furberg CD. Depressive symptoms and risks of coronary heart disease and mortality in the elderly: The Cardiovascular Health Study. *Circulation* 2000;102:1773-1779.

Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD for the PREVENT Investigators. Gender bias and underutilization of lipid lowering therapy in CAD patients at academic U.S. and Canadian Medical Centers. *Arch Intern Med*. *Arch Intern Med* 2000;160:343-7.

Klungel OH, Heckbert SR, Longstreth, Jr. WT, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HGM, de Boer A, Psaty BM. Antihypertensive drug therapies and the risk of ischemic stroke. *Arch Intern Med* 2001;161:37-43.

Pocock S, Furberg CD. Procedures of data and safety monitoring committees. *Am Heart J* 2001;141:289-294.

Pressel SL, Davis BR, Wright Jr, J, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Payne G, Einhorn PT, Nwachuku C, Furberg CD. Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Trial to Prevent Heart Attack Trial Controlled Clin Trials (ALLHAT). *Control Clin Trials* 2001;22:29-41.

Wittes J, Palensky J, Asner D, Julian D, Boissel J-P, Furberg CD, Kulbertus H, Pocock S, Roniker B. Experience collecting interim data on mortality: An example from the RALES Study. *Curr Control Trials Cardiovasc Med* 2001;2:59-62.

Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard V, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation* 2001;103:163-182.

Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard V, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke* 2001;32:280-299.

Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O'Leary DH, Bryan RN, Anderson M, Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. *Arch Intern Med* 2001;161:1183-1192.

Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? *J Am Coll Cardiol* 2001;37:1456-60.

Furberg CD. The usefulness of information on HDL-cholesterol. Potential pitfalls of conventional assumptions. *Curr Control Trials Cardiovasc Med* 2001;2:107-108.

Kaplan RC, Heckbert SR, Koepsell TD, Furberg CD, Polak JF, Schoen RE, Psaty BM for the Cardiovascular Health Study Investigators. Risk factors for hospitalized gastrointestinal bleeding among older persons. *J Amer Geriatr Soc* 2001;49:126-133.

Longstreth WT Jr., Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD for the Cardiovascular Health Study Collaborative Research Group. Frequency and predictors of stroke death in 5888 participants in the cardiovascular health study. *Neurology* 2001;56:368-375.

BIBLIOGRAPHY: (Journal Articles Continued):

Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD for the Heart and Estrogen/progestin Heart Replacement Study (HERS) Investigators. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. *J Am Coll Cardiol* 2001;38:705-711.

Heckbert SR, Kaplan RC, Weiss NS, Psaty BM, Lin D, Starr JR, Furberg CD, Anderson GD, LaCroix AZ. Risk of recurrent coronary events in relation to use and recent starting of postmenopausal hormone therapy. *Arch Intern Med* 2001;161:1709-1713.

Sinzinger H, Lupattelli G, Chehne F, Oguogho A, Furberg CD. Isoprostane 8-epi PGF_{2α} is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co enzyme-A-reductase inhibitor therapy. *J Clin Pharma Therapeutics* 2001;26:303-310.

Furberg CD, Cutler JA, Davis BR for the ALLHAT Collaborative Research Group. Status of alpha-blocker therapy

in the treatment of hypertension: Findings of ALLHAT. In: Braunwald E, Fauci AS, Isselbacher KJ, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. *Harrison's Online* 2001. www.harrisononline.com.

Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. *Curr Control Trials Cardiovasc Med* 2001;2:205-207.

Ferrucci L, Furberg CD, Penninx B WJH, Di Bari M, Williamson JD, Guralnik JM, Applegate WB, Pahor M. Treatment of systolic hypertension in older patients. Who should be treated more aggressively? *Circulation* 2001;104:1923-1926.

Balkrishnan R, Furberg CD. Developing an optimal approach to global drug safety. *J Intern Med* 2001;250:271-279.

Rautaharju PM, Nelson JC, Kronmal RA, Zhang Z-M, Robbins J, Gottdiener J, Furberg C, Manolio T, Fried L, Feldman A. Usefulness of T axis deviation as an independent risk indicator for cardiac events in older men and women free from coronary heart disease. The Cardiovascular Health Study (CHS). *Am J Cardiol* 2001;88:118-123.

Furberg CD. A new era in hypertension research: discussing the findings of ALLHAT. *Curr Control Trials Cardiovasc Med* 2001;2:249-250.

Furberg CD, Psaty BM, Pahor M, Alderman MH. Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and other studies of hypertension. *Ann Intern Med* 2001;135:1074-1078.

Fitzpatrick A, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives and incident prostate cancer. *Ann Epidemiol* 2001;11:534-542.

Furberg CD, Evans GW. B-mode ultrasonography -- A valuable research tool. *Evid Based Cardiovas Med* 2001;5:49-50. [Commentary].

Pahor M, Psaty BM, Alderman MH, Applegate WB, Furberg CD. Blood-pressure-lowering treatment. *Lancet* 2001;358:152-153.

Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, MacMahon SW, Shepherd J for the PPP Investigators. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: The Prospective Pravastatin Pooling project. *Eur Heart J* 2002;23:207-215.

Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/progestin Replacement Study: Lessons learned. *Circulation* 2002;105:917-922.

BIBLIOGRAPHY: (Journal Articles Continued):

Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepard J, Keech A, Furberg CD. Coronary heart disease in patients with LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. *Circulation* 2002;105:1424-1428.

Furberg CD. Doxazosin, an inferior antihypertensive agent? *J Human Hyperten* 2002;16:375-377.

Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II): 2. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy. *JAMA* 2002;288:58-66.

Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Furberg CD, Cooper L, Psaty BM, for the Cardiovascular Health Study Investigators. Calcium channel blocker use and gastrointestinal bleeding among older adults. [Letter to the Editor]. *Age & Ageing* 2002;31:217-220.

Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: Influence of LV systolic function. The Cardiovascular Health Study. *Ann Intern Med* 2002;137:631-639.

Longstreth WT Jr., Dulberg C, Manolio TA, Lewis MR, Beauchamp NJ, O'Leary D, Carr J, Furberg CD. Incidence, manifestations and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly. The Cardiovascular Health Study. *Stroke* 2002;33:2376-2382.

Mancini GBJ, Miller M, Evans GW, Byington R, Furberg CD, Pitt B, for the PREVENT Study Group. Post-hoc analyses of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). *Am J Cardiol* 2002;89:1414-1416.

Davis BR, Cutler JA, Furberg CD, Wright JT Jr., Farber MA, Felicetta JV, Stokes JD for the ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. *Ann Intern Med* 2002;137:313-320.

Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Cardiovascular disease risk status in elderly persons with renal insufficiency. *Kidney International* 2002;62:997-1004.

Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. *J Clin Epidemiol* 2002;55:654-664.

Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, Volpe M, Jackson R. Hypertension Guidelines: Criteria that might make them more clinically useful. *Am J Hyperten* 2002;15:917-923.

Byington RP, Furberg CD, Herrington DM, Applegate W, Herd A, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Shields K, for the HERS Research Group. Effect of estrogen + progestin on progression of carotid atherosclerosis in postmenopausal women with documented heart disease: The HERS B-mode Substudy. *Arterio Thromb Vasc Biol* 2002;22:1692-1697.

Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiener J, Burke G, Weissfeld J, Enright P, Lumley T, Powe N, Furberg CD. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: The Cardiovascular Health Study. *Arch Intern Med* 2002;162:2325-2332.

BIBLIOGRAPHY: (Journal Articles Continued):

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-2997.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2998-3007.

Burke GL, Furberg CD. The evolution of public health sciences in an academic medical center. *South Med J* 2002;95:1248-1253.

Furberg CD. To whom do the research findings apply? *Heart* 2002;87:570-574.

Psaty BM, Weiss NS, Furberg CD. The PROGRESS Trial: Questions about the effectiveness of angiotensin converting enzyme inhibitors. *Am J Hyperten* 2002;15:472-474.

Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apoproteins versus lipids as indices of coronary risk and as targets for statin treatment. *Lancet* 2003;361:777-780.

Vittinghoff E, Shlipak M, Varosy PD, Furberg CD, Ireland CC, Kahn SS, Blumenthal R, Barrett-Conner E, Loh E, Hulley S, for the HERS Research Group. Risk factors and secondary prevention in women with heart disease: The Heart and Estrogen/progestin Replacement Study (HERS). *Ann Intern Med* 2003;138:81-89.

Klein R, Klein BEK, Marino EK, Kuller LH, Furberg CD, Burke GL, Hubbard LD. Early age-related maculopathy in the Cardiovascular Health Study. *Ophthalmology* 2003;110:25-33.

Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and pro-coagulant biomarkers in elderly persons with renal insufficiency. *Circulation* 2003;107:87-92.

Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. *JAMA* 2003;289:2534-2544.

Sinzinger H, Fitscha P, Kritz H, Furberg CD. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. *Med Sci Monit* 2003;9:88-92.

Jha AK, Varosy PD, Kanaya AM, Hunninghake DB, Hlatky MA, Waters DD, Furberg CD, Shlipak MG. Differences in medical care and disease outcomes among black and white women with heart disease. *Circulation* 2003;108:1089-1094.

Butterworth J, Furberg CD. Improving cardiac outcomes after noncardiac surgery. *Anesth Analg* 2003;97:613-5.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first step antihypertensive therapy: Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension* 2003;42:239-246.

Furberg CD, Psaty BM. Should evidence-based proof of drug efficacy be extrapolated to a "Class of Agents?" *Circulation* 2003;108:2608-2610.

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg CD, Psaty BM. Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure. [Commentary]. *ACP J Club* 2004;140:5.

Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. The impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. *JAMA* 2004;291:54-62.

Majumdar SR, McAlister FA, Furberg CD. From knowledge to practice in chronic cardiovascular disease -- A long winding road. *J Amer Coll Cardiol* 2004;43:1738-42.

Davis BR, Furberg CD, Wright Jr. J, Cutler J, Whelton P for the ALLHAT Collaborative Research Group. ALLHAT: Setting the Record Straight. *Ann Intern Med* 2004;141:39-46.

Psaty BM, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs. non-chlorthalidone-based low-dose diuretic therapies. *Research Letter. JAMA* 2004;292:43-44.

Furberg CD, Hall MA, Sevic MA. Balancing commercial and public interests. *Curr Control Trials Cardiovasc*

Med 2004;5:6.

Rhoads CS, Psaty BM, Olson JL, Furberg CD. Medications and cardiovascular health in older adults: Room for improvement in prevention and treatment. *Am J Geriatr Cardiol* 2004;13:161-167.

Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP, Lumley T, Robbins J, Burke G, Newman AB, Furberg CD. The association between lipid levels and the risks of incident myocardial infarction, stroke and total mortality: the Cardiovascular Health Study. *J Amer Geriatr Soc*; 52:1639-1647.

Psaty BM, Furberg CD. Contemplating ACTION -- long-acting nifedipine in stable angina. *Lancet* 2004;364:817-818.

Tonelli M, Isles C, Curhan GC, Tonkin A, Shepherd J, Sacks F, Furberg C, Cobbe SM, Simes J, Craven T, West M. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. *Circulation* 2004;110:1557-1563.

Shlipak MG, Stehman-Breen C, Vittinghoff E, Lin F, Varosy PD, Wenger NK, Furberg CD for the Heart and Estrogen/Progestin Replacement Study (HERS) Investigators. Cretinine levels and cardiovascular events in women with heart disease: Do small changes matter? *Am J Kidney Dis* 2004;43:37-44.

Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg CD, Kuller L, Newman A. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. *J Am Soc Nephrol* 2004;15:3184-3191.

Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and the risk of rhabdomyolysis. *JAMA* 2004;292:2622-2631.

Psaty BM, Furberg CD, Ray WA, Weiss NS. Authors' reply to Bayer's response to "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis." *JAMA* 2004;292:2658-2659.

Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between the plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. *Clin Chem Lab Med* 2004;42:1355-1363.

BIBLIOGRAPHY (Journal Articles continued):

Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB, Laragh JH, Psaty BM, Ruilope LM. Beyond hypertension: towards guidelines for cardiovascular risk reduction. *Am J Hypertens* 2004;17:1068-1074.

Bryson CL, Smith NL, Kuller L, Chaves P, Manolio T, Lewis W, Boyko EJ, Furberg C, Psaty BM. Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists. *J Am Geriatr Soc* 2004;52:1648-1654.

Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). *Am J Cardiol* 2005;95:254-257.

Furberg CD, Psaty BM, Fitzgerald GA. Parecoxib, valdecoxib, and cardiovascular risk. *Circulation* 2005;111:249.

Psaty BM, Furberg CD. COX-2 inhibitors – Lessons in drug safety. *N Eng J Med* 2005;352:1133-1135.

Longstreth, Jr WT, Arnold AM, Beauchamp, Jr. NJ, Manolio TA, Lefkowitz D, Jungreis C. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly. The Cardiovascular Health Study. *Stroke* 2005;36:56-61.

Furberg CD, Psaty BM. Hormone replacement therapy. [Commentary]. ACP J Club 2005;142:1.

The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials. Major clinical trials of hypertension. What should be done next? Hypertension 2005;46:1-6.

Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-178.

Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G. Effect of pravastatin in people with diabetes mellitus and chronic kidney disease. J Am Soc Neph 2005;16:3748-3754.

Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78.

Chan JD, Rea TD, Smith NL, Siscovick D, Heckbert SR, Lumley T, Chaves P, Furberg CD, Kuller L, Psaty BM. Association of β -blocker use with total mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). Am Heart J 2005;150:464-70.

Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with-vs-without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006;97:477-479.

Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe N, Manolio T. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: The Cardiovascular Health Study. Circulation 2006;113:2177-2185.

Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenan F, Mohiuddin S, Papdemetriou Vasilios, Proschan M, Ellsworth A, Golden J, Colon P, Crow R for the ALLHAT Collaborative Research Group. Role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 2006;113:2201-2210.

BIBLIOGRAPHY: (Journal Articles Continued):

Jungner I, Sniderman AD, Furberg CD, Aastveit AH, Holme I, Walldius G. Does LDL size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 2006;97:943-946.

Schellenbaum GD, Smith NL, Heckbert SR, Lumley T, Rea TD, Furberg CD, Lyles MF, Psaty BM. Weight loss, muscle strength and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatric Soc 2005;53:1996-2000.

DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, Burke G, Fried L, Kuller LH, Robbins J, Tracy R, Woolard N, Dunn L, Kronmal R, Nahin R, Furberg C for the GEMS Investigators. The Ginkgo Evaluation of Memory (GEM) Study: Design and baseline data of a randomized trial of *Ginkgo biloba* extract in prevention of dementia. Contemp Clin Trials 2006;27:238-253.

Califf RM for the CERTs Benefit Assessment Workshop Participants. Benefit assessment of therapeutic products. The Centers for Education and Research in Therapeutics. Pharmacoepidemiol Drug Saf 2006, Feb. 28 [Epub ahead of print].

Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA 2006;295:1704-1706.

Altman DG, Furberg CD, Grimshaw JM, Rothwell PM. Lead editorial: Trials - using the opportunities of electronic publishing to improve the reporting of randomized trials. *Trials* 2006;7:6

Furberg RD, Furberg CD. Evaluating professional performance in cardiovascular medicine. *Evid Based Cardiovas Med* 2006;10:75-78.

Stafford RS, Monti V, Furberg CD, J Ma. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the U.S. *Hypertension*. 2006;48:213-8.

Cauley JA, McTiernan A, LaCroix A, Rodabough RJ, Bauer DC, Margolis KL, Paskett E, Vitolins MZ, Furberg CD, Chlebowski RT. Statin use and breast cancer: prospective results from the Women's Health Initiative. *J Natl Cancer Inst*. 2006;98:700-7.

Rautaharju PM, Ge S, Nelson JC, Marino Larsen EK, Psaty BM, Furberg CD, Zhang Z-M, Robbins J, Gottdiener JS, Chaves P. Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary artery disease. The Cardiovascular Health Study (CHS). *Am J Cardiol* 2006;97:309-15.

Furberg CD. The COX-2 inhibitors - An update. *Am Heart J* 2006;152:197-9.

Nahin RL, Fitzpatrick A, Williamson J, Burke G, DeKosky S, Furberg C, other for the GEM Study Investigator. Use of herbal medicine and other dietary supplements in the community-dwelling elderly: Baseline data from the GEM Study. *J Am Geriatr Soc* 2006;54:1725-1735.

Kronmal RA, Barzilay JI, Smith NL, Psaty B, Kuller LH, Burke G, Savage P, Furberg C. Mortality in pharmacologically-treated older adults with diabetes in the current era of medical care: The Cardiovascular Health Study 1989-2003. *PLoS Med* 3(10): e400. DOI: 10.1371/journal.pmed.0030400.

Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety. A proposal for sweeping changes. *Arch Intern Med* 2006;166:1938-1942.

Fitzpatrick AL, Fried LP, Williamson J, Crowley P, Posey D, Kwong L, Bonk J, Moyer R, Chabot J, Kidoguchi L, Furberg CD, DeKosky ST for GEMS Study Investigators. Recruitment of the Elderly into a Pharmacologic Prevention Trial: The Ginkgo Evaluation of Memory Study Experience. *Contemp Clin Trials* 2006;27:541-553.

BIBLIOGRAPHY: (Journal Articles Continued):

The LIFE Study Investigators. Effects of a physical activity intervention on measures of physical performance: results of the Lifestyle Interventions and Independence for Elders pilot (LIFE-P) study. *J Gerontol* 2006;61A:1157-1165.

Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ, Couture P, Graaf JE, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty person/ten country panel. *J Intern Med* 2006;259:247-258.

The Lp-PLA2 Studies Collaboration. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA₂ and cardiovascular diseases. *Eur J Cardiovasc Prev Rehabil* 2007;14:3-11.

Mukamal KJ, Psaty BM, Rautaharju PM, Furberg CD, Kuller LH, Mittleman MA, Gottdiener JS, Siscovick DS. Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: The Cardiovascular Health Study. *Am Heart J* 2007;153:260-6.

Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs. An update for clinicians. A scientific statement from the American Heart Association. *Circulation*

2007;115:1634-42.

Singh S, Loke YK, Furberg C. Thiazolidinediones and heart failure: A teleo-analysis. *Diabetes Care* 2007;30:1-6.

Furberg CD. Decisions by regulatory agencies: are they evidence-based? *Trials* 2007;8:13.

Miller DP, Furberg CD, Small RH, Millman FM, Ambrosius WT, Harshbarger JS, Ohl CA. Controlling prescription drug expenditures: a case of success. *Am J Manag Care* 2007;13:473-480.

Moore TJ, Cohen MR, Furberg CD. Long-term change in serious adverse drug events reported to the FDA, 1998-2005. *Arch Internal Med* 2007;167:1752-1759.

Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. *JAMA* 2007;298:1189-95.

Sniderman AD, Holme I, Aastveit A, Furberg C, Walldius G, Jungner I. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease. *Am J Cardiol* 2007;100:217-21.

Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. *N Engl J Med* 2007;24:2522-2524.

Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. *N Engl J Med* 2007;357:67-69.

Williamson JD, Villas B, Furberg CD, Nahin R, Dekosky ST. Comparison of the design differences between the Ginkgo Evaluation Memory Study and the GuidAge Study. *J Nutr Health Aging* 2008;12:73S-79S.

Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. *Lancet* 2008;371:117-25.

Furberg CD, Soliman EZ. Double-blindness protects scientific validity. *J Thromb Haemost* 2008;6:230-31.

BIBLIOGRAPHY: (Journal Articles Continued):

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. *Consensus Statement.* Lipoprotein management in patients with cardiometabolic risk. *Diabetes Care* 2008;31:811-22.

Sniderman AD, Furberg CD. Age: A modifiable risk factor for cardiovascular disease. *Lancet* 2008;371:1547-49.

Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and correlates of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) in an elderly cohort: the Cardiovascular Health Study. *J Am Geriatric Soc* 2008;56:792-99.

Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. *JAMA* 2008;300:1439-50.

Hrynaskiewicz I, Furberg CD. Trials – encouraging innovation in randomized trial reporting. *Clinical Trial Magnifier* 2008:101-6.

DeKosky ST, Furberg CD. Turning over a new leaf: Ginkgo Biloba in prevention of dementia? *Neurology* 2008;70:1730-1.

Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L.

Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Gen Intern Med* 2008;23:509-16.

Olson N, O'Meara ES, Jenny NS, Folsom AR, Bovill EG, Furberg CD, Heckbert SR, Psaty BM, Cushman M. Lipoprotein-associated phospholipase A₂ and risk of venous thrombosis in older adults. *Am J Hematol* 2008;83:524-7.

Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: The Cardiovascular Health Study. *Circulation* 2008;118:800-7.

Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan F, Furberg CD, Johnson DA, Mahaffey K, Quigley EM. ACCF/ACG/AHA Clinical Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation* 2008;118:1894-1909.

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, for the Ginkgo Evaluation of Memory (GEM) Study Investigators. *Ginkgo biloba* for prevention of dementia. A randomized controlled trial. *JAMA* 2008;300:2253-62.

Kumar A, Prineas RJ, Arnold AM, Psaty BM, Furberg CD, Robbins J, Lloyd-Jones DM. Prevalence, prognosis, and implications of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults. Cardiovascular Health Study. *Circulation* 2008;118:2790-96.

Furberg CD. Treatment of hypertension – A failing report card. *Am J Hypertens* 2009;22:1-2.

Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *CMAJ* 2009;180:32-39.

Singh S, Furberg CD. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. *Heart* 2009;95:1-3.

BIBLIOGRAPHY (Journal Articles continued):

Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2009;360:186.

Sniderman AD, Furberg CD. Why guideline-making requires reform. *JAMA* 2009;301:429-431.

Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *J Clin Epidemiol* 2009;62:464-75.

Delaney JAC, McClelland RL, Furberg CD, Cooper R, Shea S, Burke G, Psaty BM. Time trends in the use of anti-hypertensive medications: results from the Multi-Ethnic Study of Atherosclerosis. *Pharmacoepidemiol Drug Saf* 2009 Jun 23 [Epub ahead of print].

Suzuki T, Solomon C, Jenny NS, Tracy R, Nelson JJ, Psaty BM, Furberg CD, Cushman M. Lipoprotein-associated phospholipase A₂ and risk of congestive heart failure in older adults: the Cardiovascular Health Study. *Cir Heart Fail* 2009;2:429-436.

Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study. *Atherosclerosis* 2009;209:528-532.

Furberg CD. How should one analyse and interpret clinical trials in which patients don't take the treatments assigned to them? *J R Soc Med* 2010;103:202-204.

Kuller LH, Ives DG, Fitzpatrick AL, Carlson MC, Mercado C, Lopez OL, Burke GL, Furberg CD, DeKosky ST, for the GEMS Study Investigators. Does *Ginkgo biloba* reduce risk of cardiovascular events? Circ Cardiovasc Qual Outcomes 2010;3:41-47.

Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, Delaney JAC, Siscovick DS, Larson EB, Lemaitre RN, Smith NL, Rice KM, Glazer NL, Psaty BM. MI and stroke risk associated with diuretic-based two-drug antihypertensive therapies: a case-control study. BMJ 2010;340:c103.

Furberg H, for the Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010;42:441-447.

The Lp-PLA₂ Studies Collaboration. Lipoprotein-associated phospholipase A₂ and the risk of coronary disease, stroke and nonvascular mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-1544.

Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Furberg CD, Piller LB, Pressel SL, Whelton PK. Impact of the ALLHAT/JNC7 dissemination project on thiazide-like diuretic use. Arch Intern Med 2010;170:851-858.

Brinkley TE, Lovato JF, Arnold AM, Furberg CD, Kuller LH, Burke GL, Nahin RL, Lopez OL, Yasar S, Williamson JD for the Ginkgo Evaluation of Memory (GEM) Study Investigators. Effect of *Ginkgo biloba* on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens 2010;23:528-533.

Sniderman AD, Williams K, McQueen MJ, Furberg CD. When is equal not equal? J Clin Lipidol 2010;4:83-88.

Sniderman AD, McQueen M, Contois J, Williams K, Furberg CD. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 2010;4:152-155.

Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens 2010;23:929-930.

BIBLIOGRAPHY (Journal Articles continued):

Moore TJ, Glenmullen J, Furberg CD. Thoughts and acts of aggression/violence towards others reported in association with varenicline. Ann Pharmacother 2010;44:1389-94.

Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive LDL-lowering therapy: meta-analysis of individual data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010;56:2051-66.

Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PLoS One 2010;5:e15337.

Singh S, Furberg CD. Calcium supplements increase risk of myocardial infarction. Evid Based Med 2010;15:181. Epub 2010 Nov 3.

Soliman EZ, Mendis S, Dissanayaka W, Somasundaram N, Gunaratne PS, Jayasingne IK, Furberg CD. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011;12:3-8.

Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. *Prev Med* 2011;52:10-5.

Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. *Thorax* 2011;66:383-8.

Nelson TL, Kamineni A, Furberg CD, Cushman M, Jenny N, Psaty BM, Hokanson J. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) and future risk of coronary events among type 2 diabetics: the Cardiovascular Health Study. *Diabetologia* 2011;54:329-33.

Robinson-Cohen C, Katz R, Hoofnagle AN, Cauley JA, Furberg CD, Robbins JA, Chen Z, Siscovick DS, de Boer IH, Kestenbaum B. Mineral Metabolism Markers and the Long-Term Risk of Hip Fracture: The Cardiovascular Health Study. *J Clin Endocrinol Metab* 2011;96:2186-93.

Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. *Circ Cardiovasc Qual Outcomes* 2011;4:337-45.

Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease". *Arch Intern Med* 2011;171:920-2.

Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2011;342:d3215.

BIBLIOGRAPHY (Journal Articles continued):

Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. *CMAJ* 2011; _____.

In Press or Submitted

Piller LB, Baraniuk S, Cushman WC, Cuyjet A, Dart R, Davis BR, Einhorn PT, Ford CE, Furberg CD, Graumlich J, Jafri S, Massie BM, Oparil S, Parish D, Probstfield J, Retta T, Saklayen M, Simpson LM, Thadhani U; for the ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). (Submitted)

Furberg CD, Friedman LM. Approaches to data analyses of clinical trials. (submitted)

Brancati FL, Evans M, Furberg CD, Geller N, Haffner S, Kahn SE, Kaufmann PG, Lewis CE, Nathan DM, Pitt B, Safford MM. Mid-course correction to a clinical trial when the event rate is underestimated: the Look AHEAD Study. (submitted)

Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of LDL-C, non-HDL-C and apoB as markers of cardiovascular risk. (submitted)

Sniderman AD, de Graaf J, Furberg CD. Why predict risk when we can prevent disease? The ApoB causal model of vascular disease. (submitted)

Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou

V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun D, Gauer E, Davis BR, ALLHAT Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in ALLHAT: a randomized control trial. (submitted)

Moore TJ, Furberg CD, Glenmullen J, Maltzberger JT, Singh S. Suicidal/self-injurious behavior and depression in smoking cessation treatments. (submitted)

Furberg CD, Sealey JE, Alderman MH, Laragh JH. Renin test-guided drug treatment of hypertension: the need for clinical trials. (submitted)